What is the recommended dose of Brillinta (ticagrelor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage of Ticagrelor (Brillinta)

The recommended dosage of Brillinta (ticagrelor) is a loading dose of 180 mg followed by a maintenance dose of 90 mg twice daily. 1, 2, 3

Loading Dose

  • Initial loading dose is 180 mg (typically given as two 90 mg tablets at once) 2, 3
  • Achieves significant platelet inhibition within 30 minutes of administration 2
  • Peak inhibitory effect occurs approximately 2 hours after the loading dose 2
  • Loading dose should still be administered when switching from clopidogrel to ticagrelor 2

Maintenance Dose

  • 90 mg twice daily (approximately 12 hours apart) for continued therapy 1, 2, 4
  • Twice-daily dosing is essential for maintaining consistent platelet inhibition due to ticagrelor's pharmacokinetic profile 4, 3
  • When used with aspirin, the recommended aspirin maintenance dose is 81 mg daily 1, 2

Duration of Therapy

  • For patients with drug-eluting stents (DES) or bare-metal stents (BMS): continue therapy for at least 1 year 1
  • For minor ischemic stroke or high-risk TIA: dual antiplatelet therapy with ticagrelor and aspirin for 30 days 2
  • Continuation beyond 1 year may be considered in some patients with DES (Class IIb recommendation) 1

Special Considerations

  • Ticagrelor should be avoided in patients with prior history of intracranial hemorrhage 5, 2
  • Use with caution in patients with prior stroke or TIA due to increased risk of intracranial bleeding 2
  • For patients who experience a cerebrovascular event while on ticagrelor, switching to clopidogrel (75 mg daily) is appropriate 5
  • Discontinue ticagrelor at least 5 days before planned surgery 2
  • If a dose is missed, the patient should take their next dose at its scheduled time (do not double the dose) 4

Pharmacological Advantages

  • Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that doesn't require hepatic conversion to an active metabolite 2, 4, 3
  • Provides more rapid onset and more consistent inhibition of platelet aggregation compared to clopidogrel 3, 6
  • Studies show greater platelet inhibition with ticagrelor compared to clopidogrel in both clopidogrel-experienced and -naïve patients 3, 6

Common Dosing Errors

  • If an accidental double dose is taken, skip the next scheduled dose and resume normal twice-daily dosing the following morning 4
  • Monitor for signs of bleeding after any dosing errors, particularly in elderly patients (≥75 years) and those with low body weight (<60 kg) 4
  • Patient compliance with twice-daily dosing should be reinforced to prevent medication errors 4

Ticagrelor's superior platelet inhibition compared to clopidogrel has been demonstrated in clinical trials, showing reduced rates of cardiovascular death, myocardial infarction, and stent thrombosis, though with a slightly increased risk of minor bleeding 3, 7, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Ticagrelor and Aspirin Loading Doses in Posterior Circulation Stroke

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Accidental Double Dose of Ticagrelor

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Switching from Ticagrelor to Clopidogrel in Patients with Acute Cerebrovascular Events

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.